Evidence, read properly.
Short analyses on live clinical-trial data: what the registry shows, what it cannot show, and what a team should do about it. Every number carries its source and its date.
A registry date is not a readout: five ways ClinicalTrials.gov misleads a CI team
Five traps, sized on today's registry, and the rule that disarms each one.
Immunology landscapeLupus crowds Phase 1. Psoriasis crowds Phase 3. What crowding by phase tells R&D and BD.
Rheumatoid arthritis and lupus are front-loaded; psoriasis and Crohn's are crowded at the finish line.
Readout watch7 of 10 active EoE trials reach primary completion in 2026. How to watch a readout window.
Three EoE trials have finished primary data collection; two estimates are unconfirmed.
Clinical operationsChina hosts 28 of 48 recruiting industry atopic dermatitis trials. What that means for site selection.
China now appears in more than half of recruiting industry atopic dermatitis trials.
FeasibilityGermany and Canada pair deep Crohn's experience with light competition. A registry proxy for country selection.
Experience versus competition, country by country, for Phase 2â3 Crohn's disease.
AI, governedAI proposes, the analyst decides: governed AI in competitive intelligence
Why AI should read the question and never supply the number.
MethodOne conversation is an anecdote; three are a finding. Primary sources decide, secondary sources direct the search.
Why AI should aim the primary effort, and how three independent sources turn an anecdote into a finding.
Get the next one first.
One analysis every two weeks, on live data. Subscribe in the footer, or bring your own question to a pilot.